Related Experiment Videos
Restenosis: Relationship with Thrombosis
1Cardiology Division, Department of Internal Medicine, University of Texas Health Sciences Center, 6431 Fannin, Room MSB-246, Houston, TX 77025-0708, USA. Smalling@heart.med.uth.tmc.edu
Insights
Coronary restenosis after angioplasty remains a challenge. This review explores the role of the hemostatic system in restenosis and potential therapies to inhibit it.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Hemostasis Research
Background:
- Percutaneous coronary intervention (PCI) has evolved significantly since 1977.
- Despite advances, chronic restenosis of dilated coronary lesions persists as a major clinical issue.
- Restenosis involves vessel recoil, remodeling, hemostatic activation, thrombosis, and neointimal hyperplasia.
Purpose of the Study:
- To review the mechanisms of coronary restenosis.
- To investigate the role of the hemostatic system in the restenotic process.
- To discuss potential therapeutic strategies targeting the hemostatic system to prevent restenosis.
Main Methods:
- Literature review of studies on coronary angioplasty and restenosis.
- Analysis of the pathophysiology of neointimal hyperplasia and thrombosis.
- Evaluation of existing and potential anti-hemostatic therapies for restenosis.
Main Results:
- Coronary stenting mitigates vessel recoil and remodeling but not restenosis.
- Thrombosis at the injury site is a key factor in neointimal hyperplasia and restenosis, particularly in animal models.
- The hemostatic system plays a significant role in the development of restenosis.
Conclusions:
- No definitive therapy currently prevents restenosis after PCI.
- Targeting the hemostatic system presents a promising avenue for preventing chronic restenosis.
- Further research into anti-hemostatic drugs and techniques is warranted to combat restenosis.
Abstract:
Coronary balloon angioplasty was first used in 1977; since then, indications for percutaneous coronary intervention have expanded. However, despite significant advances in reducing the incidence of acute complications, chronic restenosis of dilated lesions remains a serious and frequent problem. The mechanisms of restenosis can be described as a combination of effects involving three main components: vessel recoil and remodeling, hemostatic activation and thrombus formation, and neointimal hyperplasia. Thrombosis is associated with vascular and plaque injury. In animal models thrombus at the injury site is a major determinant of intimal hyperplasia and restenosis. Although the introduction of coronary stenting has limited the effect of vessel recoil and remodeling, no effective therapy is yet available to prevent restenosis. This article reviews the potential role of the hemostatic system in restenosis and those drugs and techniques that may inhibit its effect on the restenotic process.